• About
    ▼
    • Overview
    • Leadership
    • Our Team
    • Board of Directors
    • Investors
  • Science
    ▼
    • Overview
    • Highly Cytotoxic T Cells
    • KLRG1
    • Abcuro Publications
    • Other Publications
  • Pipeline
    ▼
    • Overview
    • Ulviprubart
    • IBM
    • T-LGLL
    • T and NK Cell Lymphomas
    • Additional Indications
  • Clinical Trials
  • News
  • Careers
  • Contact
Investors

Investors

Abcuro

Breakthrough Therapies for Autoimmune Diseases & Cancer

  • About
    • Overview
    • Leadership
    • Our Team
    • Board of Directors
    • Investors
  • Science
    • Overview
    • Highly Cytotoxic T Cells
    • KLRG1
    • Abcuro Publications
    • Other Publications
  • Pipeline
    • Overview
    • Ulviprubart
    • IBM
    • T-LGLL
    • T and NK Cell Lymphomas
    • Additional Indications
  • Clinical Trials
  • News
  • Careers
  • Contact

Investors

abrdn

January 31, 2025

Bain Capital Life Sciences

August 17, 2023

BlackRock

August 18, 2023

Eurofarma

August 17, 2023

Foresite Capital

February 11, 2025

Hongsen Investment

September 17, 2021

Mass General Brigham Ventures

September 17, 2021

NEA

February 11, 2025

New Leaf Venture Partners

August 17, 2023

Pontifax

September 17, 2021

RA Capital

September 17, 2021

Redmile Group, LLC

August 17, 2023

Samsara Biocapital

September 17, 2021

Sanofi Ventures

September 17, 2021

Soleus Capital

August 17, 2023

Privacy Site Credits Terms of Use

© 2025 Abcuro